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GENERAL THORACIC SURGERY 
PULMONARY RESECTION 
FOR INVASIVE 
ASPERGILLUS INFECTIONS 
IN IMMUNOCOMPROMISED 
PATIENTS 
Standard antifungal medical therapy of invasive pulmonary aspergillosis that 
occurs in immunocompromised patients with hematologic diseases with neutropenia 
or in liver transplant recipients results in less than a 5% survival. In view of these 
dismal mortality rates, we adopted an aggressive approach with resection of the 
involved area of lung along with systemic antifungal therapy when localized invasive 
pulmonary aspergillosis developed in these patients. Between January 1987 and 
December 1993, 14 patients with hematologic diseases and 2 liver transplant 
recipients underwent resection of acute localized pulmonary masses uggestive of 
invasive pulmonary aspergillosis a median of 7.5 days (range 1 to 45 days) after the 
diagnosis was clinically suggested and confirmed by chest computed tomographic 
scans. Operative procedures done included two pneumonectomies, one bilobectomy 
with limited thoracoplasty, nine lobectomies, and five wedge resections (one patient 
with hematologic disease had two procedures). All patients were treated before and 
after the operation with antifungal agents. Nine (64%) of 14 patients with hemato- 
logic disease and 2 (100%) of 2 liver transplant recipients urvived the hospitaliza- 
tion with no evidence of recurrent Aspergillus infection after a median 8 months of 
follow-up (range 3 to 82 months). The five hospital deaths (all patients with hematologic 
diseases) occurred amedian of 20 days after operation from diffuse alveolar hemorrhage 
in three, graft-versus-host disease in one, and multiple organ system failure with 
presumed isseminated AspergiUus infection in one. Four of the five deaths were in 
patients with allogeneic bone marrow transplants. Two of the three patients requiring 
resection of multiple foci of infection died, as did the only patient who was preoperatively 
ventilator dependent. In immunocompromised patients with hematologic diseases or 
liver transplantation with invasive pulmonary aspergillosis, early pulmonary resection 
should be strongly considered when the characteristic clinical and radiographic pictures 
appear. (J TItORAC CARDIOVASC SURG 1995;109:1182-97) 
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p ulmonary infection is a major cause of morbidity 
and mortality in patients with compromised im- 
mune defenses from any cause. 1Although bacterial 
infections are more frequent, invasive fungal infec- 
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tions occur commonly and carry higher risks in these 
immunocompromised hosts. One of the most seri- 
ous opportunistic pathogens that may result in inva- 
sive pulmonary infections is Aspergillus. This fungus 
poses a significant hreat to patients with cancer, 
especially when they have neutropenia, nd to im- 
munologically suppressed organ transplant recipi- 
ents. 
Invasive pulmonary aspergillosis (IPA) has been 
found at autopsy in 20% of patients who died with 
acute leukemia. 2 It may be diagnosed premortem in
as many as 21% of patients with leukemia with a 
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subsequent 67% or higher mortality rate from this 
fungal infection. 3 Among the bone marrow trans- 
plant population, invasive Aspergillus infection oc- 
curs in 4% to 38% of patients 4 and is a highly lethal 
infection. In patients having solid organ transplan- 
tation, invasive aspergillosis develops in 2.0% of 
renal transplant recipients 5 and 4.2% of liver trans- 
plant recipients. 6 
Medical therapy with antifungal agents for IPA in 
immunosuppressed patients has yielded disappoint- 
ing results. In a recent review of the literature, 7 
standard antifungal therapy alone with amphoteri- 
cin B resulted in a greater than 94% mortality rate 
in patients who had bone marrow transplants. At the 
time of that literature review, no successful medi- 
cally treated case of IPA in a liver transplant recip- 
ient had ever been reported. 7 The propensity of 
Aspergillus to invade pulmonary blood vessels with 
the resultant hemorrhagic pulmonary infarcts and 
subsequent development of a necrotic avity sgreatly 
impedes the effective penetration of systemic anti- 
fungal agents and thereby prevents attainment of 
therapeutic lung tissue drug levels. 
Scattered reports in the 1980s documented occa- 
sional immunosuppressed patients with cancer 4' 9-12 
and renal transplant recipients 5 who were cured of 
IPA by pulmonary resection and antifungal therapy. 
Because of the dismal results from antifungal med- 
ical treatment alone, we chose in 1987 to pursue a 
more aggressive approach with these patients. We 
combined surgical resection of localized IPA with 
standard medical therapy in our immunocompro- 
mised population of patients with hematologic dis- 
eases and liver transplant recipients, and this report 
documents our results. 
Patients and methods 
Patient population. Between January 1, 1987, and De- 
cember 31, 1993, 16 consecutive immunocompromised 
patients were identified who underwent pulmonary resec- 
tions for IPA. The group consisted of 14 patients with 
hematologic diseases and 2 liver transplant recipients. 
They were studied by retrospective review of their hospital 
records and radiographic studies. For this review, patients 
were considered to be immunocompromised if they un- 
derwent high-dose chemotherapy (with or without total 
body irradiation) that caused prolonged neutropenia ( b- 
solute neutrophil count [ANC] <500 cells/ram'), with or 
without subsequent bone marrow rescue. Patients receiv- 
ing autologous bone marrow, autologous stem cell, and 
allogeneic bone marrow transplants were included. Also 
included among the immunocompromised group were 
solid organ transplant recipients. By definition, the pr/- 
mary procedure refers to either the day of transplantation 
(bone marrow or liver), the end of high-dose chemother- 
apy (in the chemotherapy only group), or the start of the 
steroid pulse for rejection treatment. 
Patients with hematologic diseases. Thirteen patients 
had hematologic malignancies and one had refractory 
aplastic anemia. Three had high-dose chemotherapy only 
and the rest had chemotherapy followed by marrow 
rescue. In addition to chemotherapy and marrow rescue, 
patients undergoing allogeneic bone marrow transplanta- 
tion also received 600 to 1200 cGy of total body irradiation 
before transplantation a d a posttransplantation immu- 
nosuppressive r gimen of cyclosporine, corticosteroids, 
and in some patients methotrexate or antithymocyte glob- 
ulin. Hematopoetic growth factors [granulocyte/macro- 
phage-colony stimulating factor (GM-CSF) or granulo- 
cyte-colony stimulating factor (G-CSF)] were commonly 
used in patients beginning in 1991. Cultures were obtained 
on hospital admission in all patients before their proce- 
dure. Patients were housed in rooms with high-efficiency 
particulate air filtration systems. Infection control proto- 
cols have been described in more detail previously. 13 
Liver transplant recipients. Two patients in our overall 
group were liver allograft recipients. The standard liver 
transplant protocols for antibiotic prophylaxis, monitor- 
ing, infection control and surveillance procedures, immu- 
nosuppression, rejection treatment, and antibacterial nd 
antifungal infection treatment have been described in 
detail previously. 6 
Diagnosis of suspected AspergiUus infection. All febrile 
patients had cultures of blood, urine, and sputum ob- 
tained. Fungal serologic testing was not routinely done in 
any patient, because negative results do not exclude the 
diagnosis. 7 Chest radiographs were done at least twice a 
week. Chest computed tomographic (CT) scanning was 
commonly done and results were believed to be suggestive 
of fungal infection if there was a new nodule with or 
without cavitation, a halo, or a hazy or sharp margin, by 
criteria reported previously. 14 Diagnostic bronchoscopy 
with bronchoalveolar vage was done in most patients in 
whom a new parenchymal bnormality on chest radio- 
graph developed. Percutaneous needle biopsy of the lung 
nodule was done on some patients. 
Probable IPA was suspected in patients with a new 
pulmonary infiltrate specially if the infiltrate was nodular 
or cavitary on chest CT scan, with or without any of the 
following: (1) new fever persisting despite antibiotic treat- 
ment; (2) new respiratory symptoms uch as dyspnea, 
cough, hemoptysis, or pleuritie chest pain; (3) sputum or 
pulmonary lavage fluid showing typical histologic findings 
or cultures positive for Aspergillus pecies; or (4) percuta- 
neous needle biopsy material from the lung infiltrate 
showing typical histologic findings or culture positive for 
Aspergillus pecies. Most patients with strongly suspected 
IPA were evaluated for evidence of disseminated infec- 
tion in another major site; for example, a brain CT scan 
was done to look for indications of cerebral aspergillosis. 
If no major distant site of infection was located and the.. 
suspected IPA appeared to be localized to one lung, then 
patients in medically operable condition underwent a
thoracotomy with pulmonary resection. 
Surgical treatment. All pulmonary resections were, 
done through aposterolateral thoraeotomy incision with a 
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Table  I. Summary of  clinical presentations of  patients with Aspergillus infection 
Patient Age Other medical Primary - 
No. (yr) Sex Primary diagnos& problems procedure Aspergillus presentation 
Hemato- 
logic 
disease 
1 
2 
36 F Acute monoblastic leukemia Tooth abscess High-dose chemotherapy CXR, CT, fever 
48 M Acute myelogenous leukemia None High-dose chemotherapy Fever, CXR, cough, chest 
pain, CT 
59 M Acute myelogenous leukemia Renal insufficiency, High-dose chemotherapy Fever, CXR, cough, chest 
hypertension pain, CT 
32 M Hodgkin's disease None Auto BMT CXR, CT, fever, chest pain 
46 F Hodgkin's disease None Auto PSCT CXR, fever, chest pain, 
cough, CT 
43 M Non-Hodgkin's lymphoma Prior melanoma Auto PSCT Fever, CXR, CT 
51 F Hodgkin's disease Hypothyroidism Auto PSCT Fever, dyspnea, CXR CT 
55 M Non-Hodgkin's lymphoma Emphysema Auto PSCT Fever, cough, CXR, CT 
47 M Non-Hodgkin's lymphoma None Auto PSCT Fever, CXR, CT 
10 
11 
12 
13 
14 
Liver 
trans- 
plant 
15 
16 
20 F Aplastic anemia Non-Aspergillus fun- Allo BMT Chest pain, CXR, fever 
gal infection on 
elbow 
49 M Acute myelogenous leukemia Chronic hepatitis B Allo BMT CXR, CT, fever, respiratory 
failure 
29 M Acute myelogenous leukemia Diffuse interstitial Allo BMT Fever, CXR, CT, respira- 
lung disease tory failure 
40 F Chronic myelogenous leukemia None Allo BMT CXR, CT 
26 F Acute myelogenous leukemia None Allo BMT CXR, fever, dyspnea, chest 
pain 
57 M Cryptogenic cirrhosis Chronic pancreatitis Liver transplant CXR, CT, leukocytosis 
(incidental hepatoma) 
38 M Transplant rejection (liver trans- Diabetes mellitus, Liver t ansplant (rejection Fever, CXR, CT 
plant 4 years earlier) hypertension treatment) 
Allo BMT, Allogeneic bone marrow transplant; Auto BMT, autologous bone marrow transplant; Auto PSCT, autologous peripheral stem cell transplant; CT, 
chest computed tomography; CXR, chest radiograph; F, female; M, male; mediast, mediastinal; met, metastatic; NG, no growth; Sp, species. 
*Some patients with leukemia had n ANC <500 cells/mm 3 on hospital admission. Consequently, in these patients the total days ANC <500 cells/ram 3 is 
actually greater than the number listed and this is i icated by a plus sign. 
double-lumen endotracheal tube in place. The extent of 
the resection was determined by the surgeon on the basis 
of the preoperative chest CT scan and the intraoperative 
findings. Three patients had intraoperative pleural irriga- 
tion with 0.9% saline solution containing amphotericin B,
whereas the r st had intraoperative pleural irrigation with 
bacitracin and 0.9% saline solution only. Amphotericin B 
administration was started in all patients before the 
operation as soon as there was a presumed fungal infec- 
tion and the agent was continued after the operation. 
Four patients were being treated prophylactically on an 
investigational protocol before any evidence of AspergilIus 
infection was found. Postoperative care was done in a 
routine manner for pulmonary resections except for main- 
tenance of appropriate respiratory isolation procedures in 
patients with neutropenia. The time for chest tube re- 
moval was based on pleural fluid drainage and air leak. 
One patient with pleural involvement with Aspergillus had 
chest tubes converted postoperatively to open empyema 
tubes that were advanced out over 2 months on an 
outpatient basis. 
Postoperative Aspergillus diagnosis. Histologic evalua- 
tion of tissue obtained from the operation was believed to 
be diagnostic for Aspergillus when it contained character- 
istic septate hyphae that exhibited ichotomous branching 
at 45 degrees, particularly if they happened to contain 
conidial heads (sporulating structures), s The histologic 
picture also had to demonstrate hyphae invasion, areas of 
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Proven site of 
Aspergillus 
infection 
Preoperative 
invasive diagnostic procedure 
Method of diagnosis 
His~logy Cuhu~ 
ANC at time of 
Total days Days after primary Aspergillus 
ANC <500* procedure ANC presentation 
cells/mm ~ >500 eells/mm 3 (cells/mm 3)
Lung, nose 
Lung 
Lung 
Lung, pleura, 
mediast. 
nodes 
Lung 
Lung 
Lung 
Lung 
Lung 
Lung 
Bronchoscopy, nondiagnostic 
Bronchoscopy, nondiagnostic 
Bronchoscopy, nondiagnostic 
Bronchoscopy, positive 
Bronchoscopy, nondiagnostic; 
needle biopsy, positive 
Bronchoscopy, nondiagnostic 
None 
Bronchoscopy, nondiagnostic 
Broncboscopy, nondiagnostic 
Bronchoscopy, nondiagnostic 
Typical NG 31 19 0 
Typical A. fumigatus 46+ No WBC recovery 0 
Typical NG 11 13 0 
Typical A. flavus 22 18 15,660 
Typical 
Typical 
Typical 
Typical 
Typical 
Typical 
NG 27 28 600 
NG 17 17 0 
NG 26 30 100 
NG 19 15 1,200 
A. fumiga- 13 13 200 
tus, Peni- 
cillium sp 
NG 35+ 23 0 
Lung 
Lung 
Lung 
Lung, skin 
Bronchoscopy, positive Typical A. fumigatus 
Bronchoscopy, nondiagnostic Typical A. flavus, 
Legionella 
Bronchoscopy, nondiagnosfic Typical A. terreus 
None Typical A. fumigatus 
39+ 22 0 
31+ 22 2,800 
16 20 0 
31 20 0 
Lung 
Lung 
Bronchoscopy, positive; nee- 
dle biopsy, positive 
Bronchoscopy, nondiagnostic; 
needle biopsy, nondiagnostic 
Typical (incidental met. A. terreus 
hepatoma in lung) 
Typical A. flavus, 
Legionella 
0 Never <500 23,400 
0 Never <500 3,400 
infarction often with cavities containing necrotic lung 
(so-called mycotic lung sequestrumal), or thrombosis of 
pulmonary vessels. Although other rare fungi such as 
Fusarium sp. may be morphologically indistinguishable 
from Aspergillus, infections morphologically confirmed 
without culture were included in this series. However, the 
diagnosis of IPA was conclusively confirmed if an Aspergil- 
lus species was cultured from tissue. 
Follow-up. Patient records, including subsequent radio- 
graphic studies, were carefully reviewed after operation 
for evidence of recurrence of the fungal infection. We 
were successful in obtaining long-term follow-up on all 
survivors of the index hospitalization, even those who left 
the local area. The majority of all long-term survivors had 
follow-up radiographic studies including chest CT scans. 
All data summaries collected from this retrospective 
review are expressed as the mean plus or minus the 
standard eviation, median, and range. Where applicable, 
data were compared with the Student's t test; p values less 
than 0.05 were considered significant. 
Results 
Patient demographics. The patient populat ion 
ranged in age f rom 20 to 59 years with a mean of 
42.3 -+ 11.4 years (median 44.5 years). There were 
10 men and 6 women. All were white. Nine of the 16 
patients (56.3%) were cigarette smokers. 
Clinical presentation. Table I shows a summary 
of the clinical presentation of each patient. Of  the 14 
patients with hematologic diseases, 3 had high-dose 
chemotherapy only. The remaining 11 had high- 
dose chemotherapy plus rescue with autologous 
bone marrow in one (No. 4), autologous peripheral  
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Fig. 1. Thin-section contrast-enhanced chest CT image 
from patient No. 9 at a level 1 cm inferior to the carina 
demonstrating a dense 1.5 cm diameter nodular mass in 
the right upper lobe of the lung with a surrounding "halo." 
stem cells in five (Nos. 5 through 9), and allogeneic 
bone marrow in five (Nos. 10 through 14). Of the 
two patients who had orthotopic liver transplanta- 
tion, one (No. 15) had the transplant because of 
end-stage liver disease caused by cryptogenic cirrho- 
sis, which was done during the same hospitalization 
48 days before the pulmonary resection for IPA. 
The other patient (No. 16) underwent liver trans- 
plantation 4years earlier because of end-stage liver 
disease caused by non-A, non-B hepatitis, and the 
current hospital admission was for treatment of 
rejection and for a bile duct stricture, with the 
subsequent development of IPA. 
A fever higher than 38.5 ° C was the initial pre- 
senting symptom of IPA in eight patients, although 
fever was a prominent symptom in all patients 
before operation, except in one liver transplant 
patient (No. 15) who was receiving high-dose corti- 
costeroids for t eatment of acute rejection. A new 
nodular or diffuse infiltrate on routine chest radio- 
graph was the presenting abnormality of IPA in 
seven other patients. The remaining patient (No. 
10) had pleuritic chest pain as the presenting symp- 
tom. Other symptoms of IPA included cough (usu- 
ally productive) in four, pleuritic chest pain in six, 
and dyspnea in two with frank respiratory failure in 
two others. Two patients (Nos. 3 and 4, both with 
thrombocytopenia) preoperatively had a slight 
amount of blood-tinged sputum intermittently but 
no patient manifested frank hemoptysis. In addition, 
no patient had a positive blood culture for Aspergil- 
lus. In the column on Aspergillus presentation in 
Table I, the abnormal signs and symptoms listed for 
each patient are given in the chronologic order in 
which they developed. 
The initial presenting signs or symptoms of IPA in 
all patients occurred a mean of 14.3 ___ 6.5 days 
(range 8 to 29 days, median 11.5 days) after the 
primary procedure. In the patients with hematologic 
diseases, IPA initially presented after a mean of 
12.9 + 5.3 days (range 8 to 24 days, median 11.0 
days). The time to presentation was not significantly 
different for patients with allogeneic and autologous 
marrow transplants. For the two patients with liver 
transplantation, a mean of 24.5 _ 6.4 days (range 20 
to 29 days) passed after their transplant or rejection 
treatment before the initial presentation of IPA, and 
this was a significantly longer period than that in the 
overall group of patients with hematologic diseases 
(p = 0.013). 
Radiographic findings. All patients had charac- 
teristic radiographic findings. On chest radiography, 
there was the appearance of a pulmonary infiltrate, 
usually nodular, that was commonly seen at the time 
symptoms occurred. Most striking was how rapidly 
the radiographic abnormalities progressed, from a 
normal chest radiograph to the sudden appearance 
of an enlarging nodule that often increased in size 
daily despite antifungal therapy. These changes 
were most notable in patients who had neutropenia 
at the time or were receiving immunosuppressive 
drugs. Chest CT scan findings were abnormal in all 
patients and generally manifested one of two pat- 
terns described previously14: (1) dense nodular 
opacity with a hazy margin or more commonly a 
surrounding zone of intermediate attenuation (de - 
sity), called a "halo" sign, or (2) cavitary mass often 
with a discrete margin and a crescent-shaped area of 
hyperlucency surrounding or within the parenchy- 
real opacity, called an "air crescent" sign. 
One patient (No. 4) exhibited an unusual picture 
of diffuse lobar consolidation and apparent pleural 
empyema containing debris (he was shown later at 
operation to have an Aspergillus empyema plus a 
necrotic Aspergillus cavity in the lung and lymph 
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Table II. Presenting radiographic opacity compared 
with cell counts and days after procedure 
Days after 
Type of opacity WBC/mrn 3 ANC/mrn 3 procedure 
Nodu le  with or 377.8 + 408.6 33.3 _+ 70.7 16.7 -+ 7.0 
w i thout  "ha lo"  
(n = 9)* 
Cavity (n = 4)* 7575.0 + 9571.3 4675 -- 6351.6 42.8 _+ 14.5 
(p = 0.036) (p = 0.04) (p < 0.001) 
WBC, White blood cell count. 
*The data for the two patients with liver transplantation were included in 
the calculation of "days after procedure." Therefore n = 10 for the nodule 
group and n = 5 for the cavity group for that section. 
node involvement with Aspergillus). Three patients 
(Nos. 3, 6, and 9) had on chest CT scan a parenchymal 
nodular opacity with a hazy margin. Six patients (Nos. 
1, 2, 7, 10, 13, and 14) had a parenchymal nodule with 
a surrounding "halo" sign, as illustrated by a chest CT 
image from patient No. 9 (Fig. 1). Four patients (Nos. 
5, 8, 11, and 12) had a gas-containing cavitary mass, 
and two of these patients had a classic "air crescent" 
sign, as shown in a representative CT image from 
patient No. 8 (Fig. 2). The two patients with liver 
transplants had both of the common radiographic 
pictures: a nodule with a hazy margin in patient No. 16 
and a gas-containing cavitary mass in patient No. 15. 
In the 13 patients with hematologic diseases with 
transient neutropenia who had one of the two major 
radiographic pictures of IPA (nodule or cavity), the 
white blood cell count and the ANC at the time the 
CT scans were obtained both significantly correlated 
with which of the two features appeared (Table II). 
Similarly, in the same 13 patients with transient 
neutropenia plus the 2 patients with liver trans- 
plants, a significant correlation existed between the 
initial type of radiographic pattern seen on chest CT 
scan with IPA (nodular or cavitary) and the time 
from the primary procedure until the radiographic 
study was done (Table II). 
Invasive diagnostic procedures. Fourteen pa- 
tients underwent flexible bronchoscopy with bron- 
choalveolar lavage a mean of 6.8 _+ 7.2 days (range 
1 to 23 days, median 3 days) after symptoms or 
radiographic abnormalities of IPA were recognized. 
One of the 14 lavage specimens (from patient No. 4) 
grew an Aspergillus pecies on culture, although two 
others (from patients Nos. 11 and 15) demonstrated 
a typical histologic picture of Aspergillus but no 
organism grew. All three of these patients had either 
cavitary lesions (Nos. 11 and 15) or diffuse lobar 
consolidation and empyema (No. 4) on CT scan. 
Fig. 2. Contrast-enhanced chest CT image from patient 
No. 8 at the level of the carina showing a gas-containing 2.5 
cm diameter cavitary density in the right upper lobe. There is 
an intracavitary mass nd an "air crescent" sign. Other more 
caudad images (not shown) demonstrate a direct bronchial 
communication with the cavity and apparent extension of 
this mass across the major fissure into the superior segment 
of the right lower lobe (confirmed at operation). 
The other 11 bronchoscopic evaluations (78.6%) 
were nondiagnostic or demonstrated other organ- 
isms. A percutaneous needle aspiration biopsy was 
done in three patients and in two the specimen grew 
an Aspergillus pecies on culture. None of the pa- 
tients had a complication from the needle biopsy. 
White blood cell counts. Neither of the patients 
with liver transplants had neutropenia t any time 
during their hospitalization. However, all 14 of the 
patients with hematologic diseases had severe neu- 
tropenia (ANC <500 cells/ram 3) during their hospi- 
talization before the development of IPA. The mean 
duration of severe neutropenia in these patients was 
26.0 + 10.3 days (range 11 to 46+, median 26.5 
days). Four patients with acute myelogenous leuke- 
mia or aplastic anemia were admitted to the hospital 
with severe neutropenia so the total neutropenic 
duration is unknown and is indicated in Table I with 
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Table III. Summary of therapy for patients with Aspergillus infection 
Days after primary procedure On day of operation 
ANC 
Aspergillus Amphotericin Operation (cells/ Days since Thoracic surgical 
Patient No. presentation B started done Condition mm 3) admission procedure 
Hemato- 
logic dis- 
ease 
1 11 13 20 Febrile, no supp 02 Lobectomy 
2 9 7 27 Febrile, no supp 0 2 
3 8 8 14 Febrile, no supp 02 
4 8 15 48 Febrile. uremic, no 
5 8 8 53 
6 9 3 33 
7 21 11 25 
8 24 12 27 
9 12 10 16 
10 15 4 days be- a. 18 
fore trans- b. 23 
plant 
11 9 9 48 
12 
supp 02 
Febrile. no supp O 2 
Afebrile. no supp 02 
Febrile. no supp 02 
Febrile. mild dys- 
pnea, no supp Oa 
Afebrile. no supp 02 
Febrile. no supp 02 
Febrile, acidotic, ven- Multiple wedge re- 
tilator support, sections 
jaundiced 
700 31 
0 35 Pneumonectomy 
1,100 24 Lobectomy 
10,000 55 Bilobectomy, decorti- 
cation, thoraco- 
plasty 
4,700 70 Pneumonectomy 
900 1 Lobectomy 
100 31 Lobectomy 
2,800 1 Lobectomy and 
wedge resection 
1,000 24 Multiple wedge re- 
sections 
a. 0 a. 28 a. Lobectomy 
b. 1,700 b. 33 b. Wedge resection 
15,100 59 
17 I day before 49 Febrile, no supp 02 2,700 58 Wedge resection 
transplant 
13 18 6 days be- 21 Afebrile, cough, no 3,400 28 Lobectomy 
fore trans- supp 02 
plant 
14 11 12 days be- 12 Afebrile, no supp 02 0 24 Wedge resetion 
fore trans- 
plant 
29 36 48 Afebrile, no supp 02 8,300 61 Lobectomy 
20 21 23 Febrile, no supp 0 2 3,400 23 Lobectomy 
Liver 
transplant 
15 
16 
A&W,, Alive and well; AML, acute myelogenous leukemia; Asper, Aspergillus infection; ATN, acute tubular necrosis; BMT, bone marrow transplant; DAH, 
diffuse alveolar hemorrhage; met., metastatic; met. sq. cell car., metastatic squamous cell carcinoma; MOSF, multiple organ system failure; POD, postoperative 
day; recurr., recurrent; resp., respiratory; supp 02, supplemental 02. 
a plus sign after the number of days the ANC was 
less than 500 cells/mm 3. The number of days after 
the end of high-dose chemotherapy or marrow 
rescue until the ANC reached more than 500 cells/ 
mm 3 was a mean of 20.0 __+ 5.1 days (range 13 to 30 
days, median 20.0 days) for 13 patients, and one 
patient (No. 2) never had recovery of the ANC to 
greater than 500 cells/mm 3 up to the time of hospital 
discharge. 
Nine of the patients were given hematopoetic 
growth factors (GM-CSF or G-CSF) after their 
transplant and their mean time for recovery of the 
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Postoperative complications 
Amphotericin Other 
B total dosage antifungal 
(rag) agents Outcome Autopsy 
Follow-up 
(months after operation) 
None 
None 
None 
None 
835 Itraconazole 
1,600 Fluconazole 
1,525 Fluconazole 
2,189 
Herpes implex pneumonia 2,823 - -  
None 1,054 - -  
None 1,000 Itraconazole 
Atrial fibrillation 1,000 - -  
None 1,000 - -  
Resp. insufficiency, coagu- 1,700 Rifampin 
lopathy, bleeding 
Resp. failure, liver failure, 1,504 Fluconazole, 
seizures Itraconazole 
Resp. failure, sepsis, renal 
failure, MOSF, pulmo- 
nary infiltrates 
Progressive resp. failure on 
POD 2 
Bilateral pulmonary con- 
solidation 
Discharged POD 8 
Discharged POD 10 
Discharged POD 26 
Discharged POD 32 
Died POD 28 
Discharged POD 6 
Discharged POD 7 
Discharged POD 9 
Discharged POD 6 
Died POD 11 graft- 
vs-host disease, 
no Asper 
Died POD 7, cere- 
bral edema, ven- 
tilator support 
1,386 Fluconazole Died POD 20, pos- 
sible Asper ecur- 
rence 
1,164 Itraconazole Died POD 20 
7,701 Fluconazole, 
(liposomal) Itraconazole 
Discharged POD 30 
m 
DAH, ATN, 
no Asper 
None 
DAH, ATN, 
met. sq. 
cell ca., 
no Asper 
None 
DAH, no 
Asper 
Auto BMT 4 mo later; A&W, no 
Asper (40 too) 
Died of AML, no Asper (10 mo) 
Died of AML, no Asper (6 mo) 
Alive with recurr. Hodgkin's, no 
Asper (82 mo) 
Died of recurr, lymphoma, no 
Asper (8 mo) 
A&W, no Asper (8 too) 
A&W, no Asper (3 too) 
A&W, no Asper (4 too) 
Died, DAH, MOSF, no definite 
Asper (3 too) 
Prolonged air leak 
Pneumonia, resp. insuffi- 
ciency, prolonged air 
leak 
901 Itraconazole Discharged POD 43 - -  
1,080 - -  Discharged POD 84 - -  
Alive with met. hepatoma, no 
Asper (13 mo) 
A&W, no Asper (8 too) 
ANC to greater than 500 cells/mm 3 was 20.2 _+ 5.0 
days. However, this time was not significantly less 
than the recovery time to an ANC greater than 500 
cells/mm 3 in the four patients with marrow recovery 
who did not receive hematopoetic growth factors, 
which was a mean of 23.0 _+ 4.8 days (p -- 0.366). 
Finally, at the time of IPA presentation, eight 
patients had an ANC of zero and six patients had 
begun to have engraftment with a mean ANC of 
3426.7 _+ 6074.1 cel ls /mm 3 (range 100 to 15,660; 
med ian  900). 
Medica l  therapy.  A complete  summary  of thera-  
peut ic  in tervent ions  for IPA  in the pat ient  popula-  
t ion is shown in Tab le  II I .  Ant i funga l  medical  
therapy was aggressively begun with amphoter ic in  B 
in all pat ients  immediate ly  on  the suspic ion of an 
active fungal  infect ion. Four  pat ients  (Nos. 10, 12, 
13, and 14) had begun receiving prophylact ic  am- 
1 1 9 0 Robinson et aL 
The Journal of Thoracic and 
Cardiovascular Surgery 
June 1995 
photericin B through an investigational protocol 
before receiving high-dose chemotherapy and mar- 
row rescue and before IPA presentation. The total 
dosage of amphotericin B received was a mean of 
1778.9 _+ 1664.1 mg (range 835 to 7701 mg, median 
1275.0 mg). Fourteen (87.5%) of the 16 patients 
received a total dosage greater than 1000 mg. One 
patient (No. 14) was treated with liposomal ampho- 
tericin B to a high total dosage of 7701 mg and was 
a hospital survivor. The total dosage of amphoteri- 
cin B did not differ significantly between a mean of 
1807.7 _+ 1995.6 mg in the 11 hospital survivors and 
the mean dose of 1715.4 _+ 648.9 mg for the five 
nonsurvivors (p = 0.922). Renal toxicity of this drug 
often limited the dosing schedules and total dosage 
in this patient population, especially in the seven 
patients also receiving long-term cyclosporine ther- 
apy. SIX patients received itraconazole for varying 
lengths of time after lung resection when severe 
nephrotoxicity or other toxic effects forced discon- 
tinuation of amphotericin B. Five patients also 
received fluconazole to treat Candida infection, and 
one received rifampin in addition to amphotericin B 
to augment IPA treatment. 
Surgical intervention. Pulmonary resection was 
done a mean of 30.1 _+ 14.3 days (range 12 to 49 
days, median 26.0 days) after the primary procedure. 
However, the interval from IPA presentation until 
operation varied greatly with a range of 1 to 45 days 
(mean 15.8 + 15.5 days, median 7.5 days). The 11 
hospital survivors had the lung resection a mean of 
11.9 _+ 12.1 days after IPA presentation compared 
with a mean of 24.4 _+ 20.1 days in the five nonsur- 
vivors, although this trend toward a longer delay for 
operation was not statistically significant (p = 
0.140). Pulmonary resection was done a mean of 
32.9 _+ 22.1 days (median 29.5 days, range 1 to 70 
days) after hospital admission. The 11 hospital 
survivors were admitted to the hospital as inpatients 
a mean of 28.7 _+ 22.3 days before lung resection, 
but not statistically fewer days than the five nonsur- 
vivors who were admitted a mean of 42.0 _+ 21.0 
days before operation (p = 0.280). 
The overall condition of most patients at the time 
of operation was surprisingly good. On the day of 
operation, the ANC had recovered to greater than 
500 cells/mm 3 in 12 (75%) of 16 patients, and the 
mean ANC for all patients was 3387.5 _+ 4298.5 
cells/mm 3 (range 0 to i0,000, median 1900.0). Only 
one of the five hospital deaths was in a patient who 
had severe neutropenia t the time of lung resec- 
tion. For only the patients with hematologic diseases 
at the time of operation, the mean ANC of hospital 
survivors was 1844.4 _+ 3176.9, which was not signif- 
icantly different from the mean ANC of 5180.0 _+ 
5804.9 in the nonsurvivors (p = 0.184). Eleven 
(68.8%) of the 16 patients were febrile on the day of 
operation. Fifteen (93.8%) of 16 patients did not 
require supplemental oxygen on the day of opera- 
tion, but the other patient (a nonsurvivor) was 
receiving ventilator support. 
Surgical procedures done included seven lobecto- 
mies (1 death), two pneumonectomies (1 death), one 
lobectomy and wedge resection, four single or multiple 
wedge resections (2 deaths), and one bilobectomy with 
decortication and three-rib thoracoplasty. In addition, 
one patient underwent a lobectomy followed 5 days 
later by a contralateral wedge resection for a new focus 
of Aspergillus infection (a nonsurvivor). 
During the period of this case review, four other 
patients (3 patients with liver transplantation a d 1 
patient with allogeneic bone marrow transplanta- 
tion) underwent pulmonary resections (all lobecto- 
mies) because of unremitting fever and new nodular 
pulmonary infiltrates uggestive of IPA. Their clin- 
ical presentation was somewhat similar to that of the 
patients with IPA although the chest CT scan find- 
ings did not demonstrate he classic "halo" sign or 
the "air crescent" sign. Two were found to have 
Nocardia lung abscesses (both hospital survivors), 
one ventilator-dependent patient had a Candida 
lung abscess (nonsurvivor), and the patient with 
allogeneic bone marrow transplant had a mixed 
bacterial lung abscess (a hospital survivor). 
Surgical pathologic findings. Resected lung on 
all patients showed a similar picture on gross exam- 
ination consisting of hemorrhagic necrosis with vary- 
ing degrees of cavitation filled with mycotic lung 
sequestrum 1~and surrounding consolidation. The 
microscopic examination confirmed the presence of 
hemorrhagic infarction with necrotic lung invaded 
by hyphae. Methenamine silver stains revealed in all 
patients the typical histologic features of abundant 
septate hyphae with dicotomous branching at 45 
degrees often with vessel invasion and thrombosis. 
A typical example of the histologic picture (patient 
No. 12) is shown in Fig. 3. Despite typical histologic 
findings in all patients, only 9 (56.3%) of the 16 grew 
an Aspergillus species. In addition, three of these 
specimens had a mixed infection. All patients had 
IPA but three also had other sites of infection with 
Aspergillus. 
Complications. Nine (56.3%) of the 16 patients 
had postoperative complications that ul imately re- 
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Fig. 3. Photomicrograph from thesurgical specimen from patient No. 12 with a Grocott methenamine 
silver stain of lung demonstrating prominent septate hyphae exhibiting dichotomous branching at 45
degrees (large arrow) and very early conidial head (sporulating structure) formation (small arrow). Fungal 
culture from this specimen grew A. flavus (original magnification ×400). 
sulted in five deaths. As expected, the most common 
complications were of respiratory origin in 7 
(77.8%) of the 9 patients. A variety of other com- 
plications occurred and are listed in Table III. The 
occurrence of nonoliguric renal insufficiency with a 
rising serum creatinine level was common in most 
patients (present before operation in many) and was 
related to amphotericin B administration, although 
it was especially pronounced in patients also receiv- 
ing cyclosporine. Despite the immunocompromised, 
debilitated condition of most patients, the majority 
of whom were receiving steroids at the time of 
operation, no patient had an empyema, broncho- 
pleural fistula, bleeding that necessitated surgical 
exploration, residual pleural space problems, wound 
dehiscence, or deep wound infection. One patient 
(No. 16) had a late superficial wound infection 
(bacterial), which healed with conservative manage- 
ment. 
Hospital outcome. Eleven of 16 patients urvived 
the hospitalization. The nine survivors with hema- 
tologic diseases were discharged from the hospital a 
mean of 14.9 _+ 11.0 days (range 6 to 32 days, 
median 9 days) after operation. The two patients 
with liver transplants were hospitalized significantly 
longer after operation and were discharged after a 
mean of 63.5 _ 29.0 days (range 43 to 84 days) (p = 
0.002). 
The five deaths (31.3% overall mortality) oc- 
curred a mean 17.2 + 8.3 days (range 7 to 28 days, 
median 20 days) after operation. Four of the five 
deaths were in patients with allogeneic bone marrow 
transplants. Only one of the original five patients 
with allogeneic marrow transplants with IPA who 
underwent lung resection survived the hospitaliza- 
tion. Two deaths (No. 11 and 13) were the result of 
diffuse alveolar hemorrhage (DAH) with respiratory 
failure, but without any evidence of residual As- 
pergillus infection in any organ. There was incidental 
metastatic squamous cell carcinoma in the pancreas 
(primary tumor not found) discovered on autopsy in 
one of these patients (No. 11). One hospital death 
(No. 10) was a result of biopsy-proven graft-versus- 
host disease with respiratory failure, but no clinical 
evidence of Aspergillus recurrence was seen. An- 
other hospital death (No. 12) occurred as a result of 
respiratory failure with pulmonary infiltrates, sepsis, 
and multiple organ system failure and occurred in 
the only patient in the entire group of 16 in whom 
recurrent and possibly disseminated Aspergillus in- 
fection was clinically suspected; unfortunately no 
autopsy was obtained. The final death occurred in 
the only patient with autologous bone marrow trans- 
plantation (No. 5), who died 4 weeks after operation 
with Herpes simplex pneumonia nd DAH in the 
remaining lung after a pneumonectomy. 
Long-term follow-up. Long-term follow-up of 
hospital survivors was 100% complete, with a mean 
follow-up of 16.8 + 24.0 months (range 3 to 82 
months, median 8 months). Three patients have 
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subsequently died with recurrence of their malig- 
nancy at a mean of 8.0 ___ 2.0 months (range 6 to 10 
months), but none had any evidence of Aspergillus 
infection. Likewise, none of the survivors of the 
initial hospitalization has ever had any clinical evi- 
dence of recurrent Aspergillus infection. 
Discussion 
Aspergillus is a ubiquitous fungus commonly 
found in soil, stored grains, and decaying organic 
matter such as spoiled straw and hay, and it is even 
found in such extreme nvironments as the Sahara 
sands and the Arctic snow. is The fungus, first iden- 
tified in 1729 by the priest and botanist Micheli, was 
probably named for the perforated globe (aspergil- 
lum) used for sprinkling holy water due to its 
resemblance to the radiating spores (conidial head) 
on the hyphae. 16 After the initial clinical description 
of aspergillosis n 1842, Virchow 17 in 1856 reported 
the first four cases with pathologic evidence of this 
disease on autopsy. 
Aspergillus pores are airborne organisms usually 
present in the air, and undoubtedly inhalation of 
them is extremely common. Yet their virulence is 
low and production of disease is rare. Involvement 
of the lungs with this fungus is the most common 
because the portal of entry is usually the respiratory 
tract. Hinson, Moon, and Plummer 16 in 1952 classi- 
fied pulmonary aspergillosis nto three types. First, 
the noninvasive allergic form results in respiratory 
symptoms as a result of an immunologic reaction to 
the fungus in the tracheobronchial tree. Second, 
saprophytic disease results from colonization of 
preexisting cavities in the lung, leading to the for- 
mation of a tangled mass of hyphae, blood elements, 
and debris in the cavity termed a mycetoma (fungus 
ball) or classic aspergilloma. These lesions have 
been classified into simple or complex aspergillomas 
depending on the extent of surrounding parenchy- 
real disease. The saprophytic form is the most 
common manifestation of pulmonary aspergillosis, s 
may require surgical excision because of bleeding 
(sometimes life-threatening) from erosion into sur- 
rounding pulmonary vessels, and generally is a 
chronic process quite unlike the invasive third type. 
The third type, the septicemic type or IPA, occurs 
almost exclusively in immunocompromised hosts. It 
arises in necrotizing bronchopneumonia with fur- 
ther invasion of lung parenchyma nd pulmonary 
vessels leading to thrombosis and hemorrhagic 
infarction, and ultimately the fungus may dissem- 
inate. 
The development ofnosocomial IPA in an immu- 
nocompromised patient is a potentially devastating 
complication, occurring in as few as 4.5% of patients 
with bone marrow transplants of all types is to as 
many as 20% of allogeneic bone marrow transplant 
recipients. 19 In patients with neutropenia and acute 
leukemia undergoing standard chemotherapy, IPA 
has been diagnosed antemortem in 21%. 11 In con- 
trast, invasive aspergillosis without neutropenia may 
develop in 2% of patients with renal transplants 5 
and 1.5% 20 to 4.2% 6 of patients with liver trans- 
plants. However, considering the high mortality in 
all immunocompromised patients, the development 
of IPA is a serious complication. 
For patients with hematologic diseases and those 
undergoing bone marrow transplantation, the risk of 
the development of IPA progressively rises with the 
increasing number of neutropenic days, reaching a 
70% incidence by 34 or more days of neutropenia. 2° 
The mean neutropenic period for patients in the 
current series was 26.0 _ 10.3 days, which clearly 
places most of our patients in this high-risk group. 
Some series indicate that an age older than 30 years 
increases the incidence of IPA, as does mismatching 
of bone marrow allograft recipients, is Cytomegalo- 
virus (CMV) infection, which itself is immunosup- 
pressive, has been demonstrated bysome to predis- 
pose patients to IPA, 19 as does the presence of 
higher grade graft-versus-host disease. Is Corticoste- 
roid therapy is another independent risk factor for 
aspergillosis. 21Because therapy with corticosteroids 
generally accompanies the use of cyclosporine in 
graft-versus-host prophylaxis, corticosteroids further 
compound the immunosuppression of patients with 
allogeneic bone marrow transplants and increase 
their overall risk of lethal IPA. 7' 13 Other factors that 
may contribute to an elevated risk include damage 
to the mucocutaneous barriers by fungus, impaired 
humoral immunity related to side effects of therapy, 
and the loss of resistance to colonization by the use 
of antibiotics. 22 All of the patients with hematologic 
diseases in the current series had one or more of 
these risk factors. 
In patients with solid organ transplants, predis- 
posing factors for development of aspergillosis in- 
clude recent treatment for acute rejection (both 
liver transplant patients in the current series were 
treated for rejection), recent CMV infection, and 
multiple transplantations. 5 Factors also found spe- 
cifically in patients with liver transplants include 
retransplantation, reintubation, bacterial infections, 
prolonged antibiotic use, increased intraoperative 
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blood transfusion requirements, increased number 
of corticosteroid boluses, use of OKT3, vascular 
complications, rising levels of serum creatinine, 
Roux-en-Y biliary reconstruction, and urgent rans- 
plant status. 6 Many of these factors were present in 
the two patients with liver transplantation i the 
present series. 
Establishment of an early antemortem diagnosis 
of IPA is important if treatment is to be successful. 
Symptoms are most likely to occur during the period 
of neutropenia, and in our series of patients with 
hematologic diseases ymptoms began a mean of 13 
days after the marrow transplant or the end of 
chemotherapy, when 50% of these patients had an 
ANC of zero. For the patients with liver transplants, 
presentation of IPA symptoms or signs occurred 
later at a mean of 25 days. The clinical presentation 
most commonly includes unexplained and unremit- 
ting fever not responsive to antibacterial gents, 4 a 
symptom present in 94% of patients in the present 
series and missing only in the one patient receiving 
high-dose corticosteroids for rejection. Pleuritic 
chest pain, seen in 38% of our patients, is seen 
frequently, along with dyspnea and cough. 23 He- 
moptysis may occur because of the vasculotropic 
nature of the fungus, which leads to pulmonary 
vessel invasion. But the reported 31% incidence of 
hemoptysis n IPA is not nearly as high as the 52% 
to 80% occurrence in classic saprophytic aspergillo- 
mas. 24 Interestingly, only 13% of patients in our 
series manifested even a minor episode of hemop- 
tysis with IPA. 
The development of a characteristic rounded 
infiltrate on the chest radiograph is a universal 
finding and when accompanied by a fever in an 
immunocompromised patient should strongly sug- 
gest IPA. 24 Mori and associates 14described the two 
major radiographic patterns of IPA seen on chest 
CT scans: nodular with or without a surrounding 
"halo" and cavitary with or without an "air crescent" 
sign. The nodular pattern appears to be the earlier 
presentation because it significantly correlates with 
a lower white blood cell count, lower absolute 
neutrophil count, and earlier occurrence after trans- 
plantation. 14 This association was also found in our 
series (see Table II). Because the cavitary pattern 
generally is seen after engraftment, this implies that 
neutrophil recovery is necessary for pulmonary cav- 
itation to occur. Przyjemski and Mattii 25 proposed 
that proteolytic enzymes released from the influx of 
granulocytes cause dissolution of necrotic lung and 
separation of sequestra from the surrounding lung 
parenchyma leading to cavity formation. This hy- 
pothesis is further strengthened by the fact that the 
most frequent presentation of IPA was cavitary in 
91% of patients with renal transplantation who 
never had neutropenia. 5 
A positive sputum culture for Aspergillus is highly- 
suggestive of infection, but may only indicate colo- 
nization. Bronchoscopy with bronchoalveolar l vage 
tends to be nondiagnostic and usually is not helpful 
because ven a positive result for Aspergillus may 
indicate only colonization and not invasive infec-. 
tion. 26 In the present series, only 19% of lavage 
samples had positive histologic results and all were 
in patients with advanced cavitary disease. Percuta- 
neous needle biopsy of the nodular infiltrate is; 
another diagnostic option and showed positive re-. 
sults in two of three of our patients. However~ 
needle biopsy often carries an unacceptably high 
risk of bleeding complications in these patients with 
thrombocytopenia. Additionally, because a nondiag- 
nostic result will generally not change therapeutic: 
plans if surgical resection is an option, this modality 
probably should be reserved for patients who would 
be treated with medical therapy only. 
Recently, a commercial test kit for Aspergillus 
infection has been described for detection of As.. 
pergillus galactomannan tigen in serum, urine, or 
both. Although a false positive result may occur in 
patients receiving certain anticancer agents uch as 
cyclophosphamide, this test reportedly facilitates 
very early detection in those patients at high risk for 
IPA, such that empiric antifungal therapy may be 
started promptly and the results of medical therapy 
are possibly improved. 27 
Definitive diagnosis of IPA early in its course is 
often difficult and a treatment delay can be uni- 
formly fatal in these immunocompromised pa- 
tients. 24 Therefore it is entirely appropriate to insti- 
tute empiric antifungal therapy with amphotericin B 
when IPA is clinically suspected. 13 Unfortunately, 
even early aggressive medical treatment of IPA 
results in a high mortality. Meyer and associates 23
reported a 100% mortality rate with medical treat- 
ment alone for IPA in their immunocompromised 
population. Wingard and colleagues 4 and Peterson 
and associates 19found the same 100% mortality rate 
in-their bone marrow transplant populations. Den- 
ning and Stevens 7 in their extensive 1990 review 
found an overall 94% mortality rate with medical 
therapy of IPA in 13 collected series of bone marrow 
transplant recipients. 
For patients with solid organ transplants, the 
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mortality rate from IPA in patients with renal 
transplantation treated medically was lower at 38% 
although 60% of survivors lost their allograft kidney 
because rejection episodes were not treated while 
they were being treated for IPA. 5 However, the 
mortality rate from IPA in liver transplant recipients 
with medical therapy has been shown to be much 
worse and in multiple series approaches 100%.  28 
Scattered early anecdotal reports have appeared 
of IPA cures resulting from combining pulmonary 
resection with antifungal medical therapy in immu- 
nocompromised patients. Wingard and associates 4 
in their bone marrow transplant population had only 
one survivor with IPA, and that patient underwent 
pulmonary resection of the infection site in addition 
to amphotericin B therapy. This was also the expe- 
rience of Meyer and colleagues 23in one patient 15 
years earlier at the Memorial Sloan-Kettering Can- 
cer Center. In their 1987 review, Kibbler and asso- 
ciates 11 reported their own series plus patients from 
the literature for a total of eight surgical cures of 
IPA with no surgical mortality in patients with 
neutropenic leukemia. For solid organ transplanta- 
tion, Weiland and colleagues 5 reported three survi- 
vors of lung resection and amphotericin B treatment 
of IPA in their renal transplant population (also, all 
allograft kidneys urvived). 
In view of the dismal results of medical therapy 
of IPA and these promising early surgical results, 
we adopted an aggressive surgical approach in 
1987 for the present series in which immunocom- 
promised patients with clinical evidence strongly 
suggestive of IPA underwent pulmonary resection 
along with amphotericin B therapy. In our series, 
all three patients receiving high-dose chemother- 
apy and five of six autologous marrow rescue 
patients survived, free of recurrent Aspergillus 
infection. The one death in the autologous mar- 
row group was caused by Herpes simplex pneumo- 
nia and later DAH in the remaining lung after 
pneumonectomy for removal of a lung destroyed 
by prior radiation therapy and cavitary IPA. Re- 
sults after pulmonary resection in patients with 
allogeneic bone marrow transplants with IPA 
have been less rewarding for us and others. 24 Four 
of five of our patients with allogeneic transplan- 
tation did not survive the hospitalization: two died 
of respiratory failure from DAH, another died of 
graft-versus-host complications, and the fourth 
patient died with multiple organ system failure 
but possibly had disseminated Aspergillus infec- 
tion. DAH, which is probably a subset of idio- 
pathic interstitial pneumonitis (a common cause 
of death in allogeneic bone marrow transplan- 
tation29), is a poorly understood, high-mortality 
condition that caused three of the five postoper- 
ative deaths in our series. It appears to be asso- 
ciated with renal insufficiency, advanced age, and 
white blood cell recovery, but it is not related to 
Aspergillus infections. 3° Finally, both patients with 
liver transplants survived lung resection for IPA 
and are still living with no evidence of recurrent 
Aspergillus infection. The overall survival from 
IPA for our surgically treated patients with hema- 
tologic diseases is 64% and survival is 100% for 
our liver transplant group. 
Since we began our study, several other surgical 
series have been reported. Lupinetti and associ- 
ates 24 reported on five pediatric patients with 
leukemia treated with chemotherapy and alloge- 
neic bone marrow rescue who underwent pulmo- 
nary resection for IPA. One patient operated on 
two months before transplant was cured of IPA 
although later died of CMV pneumonia; the other 
four died 24 to 194 days after operation of 
disseminated Aspergillus infection (2 patients), 
Aspergillus pneumonia (1 patient), and central 
nervous ystem leukemia (1 patient). Young and 
associates 31 reported 100% hospital survival in 
eight patients with neutropenia with malignancies 
(4 had bone marrow transplants) who underwent 
pulmonary resections (7 lobectomies and 1 multi- 
ple wedge resections) for IPA. Wong, Waters, and 
Walesby 26 later reported a series of 16 patients 
with neutropenia (14 with high-dose chemother- 
apy only and 2 with allogeneic bone marrow 
transplantation) who underwent pulmonary resec- 
tions (13 by lobectomy or pneumonectomy and 3 
by wedge resection) for IPA, with only one post- 
operative death caused by CMV pneumonia nd 
no recurrent Aspergillus infection. 
The outlook for improvements in medical therapy 
in the near future for IPA that might challenge these 
most recent surgical results is slightly encouraging. 7 
Trials are in progress with the minimally toxic and 
very promising oral drug itraconazole (an intrave- 
nous preparation will be available soon), liposomal 
amphotericin B with its putative lower toxicity and 
improved penetration, prophylactic amphotericin B 
in patients with neutropenia, who are at high risk for 
the infection (this did not prevent IPA in 4 patients 
in our series), and combination medical therapy 
with amphotericin B to achieve synergy with flucy- 
tosine or rifampin. However, even the optimal dos- 
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age and duration of therapy of amphotericin B for 
treatment of deep mycoses is still not clear and 
possibly higher dosages may be advisable] Although 
the most common species, A. fumigatus and A. 
flavus, are generally sensitive to amphotericin B, in 
vitro susceptibility esting, despite its 5- to 21-day 
turnaround time, may play an important role when 
other therapeutic agents uch as flucytosine (which 
is not effective with all isolates) are used singly or in 
combination or when less common Aspergillus pe- 
cies are treated] 
At present, it is not clear which is the most 
effective management strategy for IPA in immu- 
nocompromised patients. The persistently high 
mortality rates with current medical management 
sways us to advocate adding the more aggressive 
surgical approach, as described in this retrospec- 
tive series and prior recent reports. 24' 26, 31 Con- 
trary to what might be expected, pulmonary resec- 
tion for localized IPA in selected patients can be 
done safely with low morbidity and mortality 
despite low or nonexistent white blood cell counts, 
thromboctyopenia, nd corticosteroid therapy, 
with only rare recurrence of the Aspergillus infec- 
tion. Results from these series suggest that early, 
complete resection with lobectomy or occasionally 
wedge resection for smaller fungal lesions along 
with excision of sufficient normal tissue to prevent 
contamination f uninfected lung should be done 
as soon as the characteristic clinical and radio- 
graphic pictures appear, without waiting for pos- 
itive cultures or other confirmatory tests or a long 
trial of antifungal medical therapy. Delaying sur- 
gery may result in life-threatening hemoptysis, 31 
greater isk for systemic dissemination asfurther 
vascular invasion by the fungal hyphae occurs, 32 
and increased risk for pleural fungal invasion with 
empyema formation. The best survival results 
from the current series and others 11' 31 favor early 
resection, preferably within the first week of 
diagnosis. 
The exact role that surgical treatment plays in 
various patient subsets in the treatment of IPA has 
yet to be defined and awaits prospective clinical 
trials. From our experience and that of oth- 
ers,24, 26, 31 patients with multiple loci of infection, 
allogeneic bone marrow transplant recipients, and 
possibly ventilator-dependent patients are less likely 
to benefit from this aggressive surgical approach. 
However, aside from these caveats, most immuno- 
compromised patients with hematologic disease and 
solid organ transplant recipients in whom this al- 
most uniformly fatal complication of IPA develops 
may expect agreatly improved likelihood of survival, 
with almost 70% of all patients in this series cured of 
the fungal infection for the long term. 
We extend our special appreciation to Dr. Susan L. 
Speaks for providing the photomicrograph (Fig. 3) used in 
this manuscript. 
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Discussion 
Dr. Zwi Steiger (Detroit, Mich.). I just have one question 
and a comment. Have you done any resections for As- 
pergillus infection before transplants to avoid possible 
complications? We, too, had massive hemoptysis n im- 
munocompromised patients. The hemoptysis was attrib- 
uted to Aspergillus infection with unfortunate conse- 
quences that, in retrospect, could have been avoided by an 
elective resection of localized disease. On the urging of 
the oncologists and infectious disease physicians, we 
started resecting these foci, with favorable results. Com- 
pared with resection of Aspergillus-infected chronic tuber- 
culosis cavities, these procedures are not technically dif- 
ficult. 
Dr. Robinson. The three patients who initially were 
treated with high-dose chemotherapy only and in whom 
Aspergillus infection later developed underwent lung re- 
section and survived. Two of the three patients ubse- 
quently had high-dose chemotherapy and bone marrow 
transplantation 3 to 4 months later and did well. This 
approach as been described in the literature with good 
results, and I think it is a reasonable course to pursue. 
Mr. Robin K. Walesby (London, England). I have a 
wide experience with this condition in London and I 
reported the cases of 16 patients 2 years ago (Wong K, 
Waters CM, Walesby RK. Surgical management of inva- 
sive pulmonary aspergillosis n immunocompromised pa- 
tients. Eur J Cardiothorac Surg 1992;6:138-43). My expe- 
rience has now unfortunately risen to 30 patients with this 
condition. 
I compliment he authors on this paper and their 
results, which are much the same as mine. I have found 
that it is important o overresect lung tissue in these 
situations. I have had to reoperate on patients on four 
occasions either to turn a wedge resection into a lobec- 
tomy or to change a lobectomy into a completion pneu- 
monectomy when the disease recurred in the remainder of 
the lung. Unfortunately, my hematologists are always 
opposed to lobectomy because their chemotherapy is 
deleterious to lung function. There is always a conflict 
between the hematologist who wants the surgeon to leave 
as much lung tissue as possible and the surgeon who needs 
to take out as much lung as is necessary because of the 
diffuse and invasive nature of the disease. Although there 
is invariably a discrete nodular aspergilloma, that is only 
part of the story. The disease is much more diffuse and can 
affect he whole lobe or the whole lung, as the description 
of IPA might lead one to believe. 
Finally, can I ask you whether you use aprotinin (Tra- 
sylol)? I have had problems in the past with excess 
bleeding. These resections are exceedingly demanding 
because all tissues are matted together by the inflamma- 
tory process. Even though preoperative infusion with 
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clotting factors and platelets is done before operation I 
have produced a dramatic decrease in blood losses with 
the use of preoperative aprotinin. 
Dr. Robinson. We have not used any supplemental 
methods to decrease bleeding problems in addition to 
platelet ransfusions and replacement of clotting factors. 
This approach as worked well for us. However, I know 
other surgeons who have had problems with bleeding in 
these patients, and this is a significant concern. So far we 
have not had to use any other therapy for hemostasis. 
I would agree with your recommendation to do wider 
resections in these cases. We tend to do lobectomies, and 
after this experience we continue to favor a wide resec- 
tion. Wedge resections were done in only four patients, 
but most were in patients who had several loci of Aspergil- 
lus infection in the same lung. However, I would agree 
that a wider resection is probably preferred. 
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